PUBLIC COMPANY
save$DYNDyne Therapeutics, Inc.
$DYN16.94+7.76%Waltham, MA, USupdated 21d ago
community read0 votes
pipeline
4
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
2Preclinical2Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
- phase2Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
- phase2Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
🐶 Hiring Signal
News
- Marrow Therapeutics debuts with $173M to tackle blood disorders in vivoMarrow Therapeutics aims to address safety and accessibility obstacles in genetic medicines by delivering therapies straight to bone marrow cells.biospace · 1d ago
- PepGen shares almost double as DM1 oligonucleotide achieves ‘best in class’ splicingMean splicing correction for PepGen’s PGN-EDODM1 was 46.5% at week 13, compared to under 30% for competitors like Dyne Therapeutics, Novartis and Ionis Pharmaceuticals.biospace · 7d ago
- Biopharma hiring hotspots: States, disciplines where demand is highestAs biopharma job openings rose this year, opportunities were greatest in Massachusetts and California and in the science/R&D and clinical disciplines, according to BioSpace data. Several other loca…biospace · 2mo ago
- Novartis RNA drug falls short in rare muscle disease studyThe failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.biopharma_dive · 2mo ago
- Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappointsWhile Novartis’ antibody-oligonucleotide conjugate failed to significantly improve hand function in patients with myotonic dystrophy type 1, the asset nevertheless showed signs of clinical activity…biospace · 2mo ago
- Capricor CEO won’t rule out legal action against FDA after negative adcommAfter an FDA advisory committee voted 9-3 on Wednesday against recommending Capricor Therapeutics’ Duchenne muscular dystrophy cardiomyopathy drug for approval, stakeholders allege an “ulterior mot…biospace · 3mo ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 4mo ago
Data sources
last refreshed 40m ago
Found something off?
comments(0)
5-min edit window · permanent after that